Kelley Lauren Coffman, MD, Responses to and Adverse Effects of Therapy With 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

Video

The hospitalist at Memorial Sloan Kettering Cancer Center discussed the results of a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.

Investigators observed a meaningful disease control rate among patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera), according to study results presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, spoke about the results of the study and the toxicities she and her colleagues observed during the trial.

Transcription:

In the predominant results, we saw that there was good benefit in terms of disease stability from the treatment. About 63% of patients had a partial response to the therapy after completing 4 cycles, about 6% had stable disease, and unfortunately about a third of the patients, about 31%, did progress.

The other notable results were the toxicities. It was consistent with what was seen in the earlier trials, where the primary toxicity was bone marrow suppression and [aspartate aminotransferase; AST]/[alanine aminotransferase; ALT] elevation. But the severity in our patient population was not quite that high. We didn’t really see any grade 3 or grade 4 toxicities.

Reference:

Coffman KL, Bodei L, Le T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. J Clin Oncol. 2021;39(suppl 3). Abstract #: 368.

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Related Content